Table 2. Pathological characteristics of the cognitively impaired subjects (CDR-SOB>0) by APOE genotype.
| ε2/ε2+ε2/ε3 | ε3/ε3 | ε3/ε4 | ε4/ε4 | P value | |
|---|---|---|---|---|---|
| Number of subjects, n | 41 | 339 | 320 | 93 | NA |
| Neuritic plaques, n (%) | <0.0001 | ||||
| None/sparse | 18 (43.9) | 49 (14.5) | 20 (6.3) | 1 (1.1) | |
| Moderate | 12 (29.3) | 97 (28.6) | 47 (14.7) | 13 (14.0) | |
| Frequent | 11 (26.8) | 193 (56.9) | 253 (79.1) | 79 (85.0) | |
| Braak NFT stage, n (%) | <0.0001 | ||||
| 0/I/II | 13 (31.7) | 35 (10.3) | 15 (4.7) | 0 (0.0) | |
| III/IV | 17 (41.5) | 82 (24.2) | 56 (17.5) | 12 (12.9) | |
| V | 4 (9.8) | 84 (24.8) | 91 (28.4) | 26 (28.0) | |
| VI | 7 (17.1) | 138 (40.7) | 158 (49.4) | 55 (59.1) | |
| CAA, n (%) | <0.0001 | ||||
| None | 20 (48.8) | 133 (39.2) | 53 (16.6) | 12 (12.9) | |
| Mild | 9 (22.0) | 101 (29.8) | 104 (32.5) | 14 (15.1) | |
| Moderate | 6 (14.6) | 64 (18.9) | 100 (31.3) | 32 (34.4) | |
| Severe | 5 (12.2) | 35 (10.3) | 54 (16.9) | 35 (37.6) | |
| Not assessed/unknown | 1 (2.4) | 6 (1.8) | 9 (2.8) | 0 (0.0) | |
| Arteriosclerosis, n (%) | 0.887 | ||||
| None | 8 (19.5) | 66 (19.5) | 46 (14.4) | 15 (16.1) | |
| Mild | 11 (26.8) | 96 (28.3) | 88 (27.5) | 26 (28.0) | |
| Moderate | 11 (26.8) | 74 (21.8) | 76 (23.8) | 19 (20.4) | |
| Severe | 3 (7.3) | 26 (7.7) | 27 (8.4) | 10 (10.8) | |
| Not assessed/unknown | 8 (19.5) | 77 (22.7) | 83 (25.9) | 23 (24.7) | |
| Atherosclerosis, n (%) | 0.829 | ||||
| Yes | 35 (85.4) | 281 (82.9) | 261 (81.6) | 79 (85.0) | |
| No | 6 (14.6) | 58 (17.1) | 59 (18.4) | 14 (15.0) | |
| Hippocampal sclerosis, n (%) | 0.560 | ||||
| Yes | 2 (4.9) | 26 (7.7) | 30 (9.4) | 7 (7.5) | |
| No | 37 (90.2) | 298 (87.9) | 286 (89.4) | 83 (89.3) | |
| Not assessed/unknown | 2 (4.9) | 15 (4.4) | 4 (1.3) | 3 (3.2) | |
| Lewy bodies, n (%) | 0.121 | ||||
| Yes | 9 (22.0) | 87 (25.7) | 112 (35.0) | 29 (31.2) | |
| No | 32 (78.0) | 250 (73.8) | 208 (65.0) | 64 (68.8) | |
| Not assessed/unknown | 0 (0.0) | 2 (0.6) | 0 (0.0) | 0 (0.0) |
Numbers in parenthesis represent column percents, that is, percent of subjects of each APOE genotype with a given neuropathologic feature. CAA = cerebral amyloid angiopathy. NA = not applicable. NFT = neurofibrillary tangles. P value is for comparison of the distribution of each neuropathological variable among APOEε2 carriers (ε2/ε2+ε2/ε3) and APOEε4 carriers (ε3/ε4+ε4/ε4).